Xintela AB (publ) (STO:XINT)
Sweden · Delayed Price · Currency is SEK 0.2220
+0.0040 (1.83%)
Mar 20, 2026, 3:28 PM CET
Xintela AB Market Cap
Xintela AB has a market cap or net worth of 191.2 million as of March 20, 2026. Its market cap has decreased by -25.60% in one year.
Market Cap
191.20M
Enterprise Value
167.99M
Revenue
2.28M
Ranking
n/a
PE Ratio
n/a
Stock Price
0.22
Market Cap Chart
Since March 22, 2016, Xintela AB's market cap has increased from 103.68M to 191.20M, an increase of 84.41%. That is a compound annual growth rate of 6.31%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 20, 2026 | 191.20M | -3.76% |
| Dec 30, 2025 | 198.68M | 5.85% |
| Dec 30, 2024 | 187.69M | 26.87% |
| Dec 29, 2023 | 147.94M | -1.74% |
| Dec 30, 2022 | 150.56M | -26.24% |
| Dec 30, 2021 | 204.12M | 2.23% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Mar 22, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Lipum AB | 304.40M |
| Elicera Therapeutics AB | 256.27M |
| Mendus AB | 242.63M |
| Sprint Bioscience AB | 210.50M |
| Initiator Pharma | 204.67M |
| AlzeCure Pharma AB | 197.65M |
| Isofol Medical AB | 177.10M |
| Magle Chemoswed Holding AB | 170.36M |